David Hardisson

10.0k total citations · 2 hit papers
158 papers, 7.0k citations indexed

About

David Hardisson is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, David Hardisson has authored 158 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 51 papers in Molecular Biology and 41 papers in Cancer Research. Recurrent topics in David Hardisson's work include Ovarian cancer diagnosis and treatment (26 papers), Cancer Genomics and Diagnostics (17 papers) and Endometrial and Cervical Cancer Treatments (17 papers). David Hardisson is often cited by papers focused on Ovarian cancer diagnosis and treatment (26 papers), Cancer Genomics and Diagnostics (17 papers) and Endometrial and Cervical Cancer Treatments (17 papers). David Hardisson collaborates with scholars based in Spain, United States and United Kingdom. David Hardisson's co-authors include David Sarrió, Gema Moreno‐Bueno, Socorro Marıá Rodríguez-Pinilla, José Palacios, Marta Mendiola, Amparo Cano, José Palacios, Francisco Calero Calero, Miriam Zimmermann and Sharon Gowan and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

David Hardisson

148 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype

2008 842 citations David Sarrió, Socorro Marıá Rodríguez-Pinilla et al. Cancer Research profile →
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

2012 783 citations Marta Mendiola, David Hardisson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Hardisson Spain	42	3.6k	2.6k	1.9k	832	756	158	7.0k
Anne‐Marie Mes‐Masson Canada	50	4.4k 1.2×	2.7k 1.1×	1.9k 1.0×	639 0.8×	1.2k 1.6×	272	9.1k
Robert Zeillinger Austria	52	4.7k 1.3×	3.7k 1.4×	3.1k 1.6×	648 0.8×	827 1.1×	284	9.3k
Yohei Miyagi Japan	47	3.4k 1.0×	2.3k 0.9×	1.8k 1.0×	421 0.5×	1.6k 2.1×	324	8.2k
Isabelle Treilleux France	47	3.1k 0.9×	3.6k 1.4×	1.7k 0.9×	722 0.9×	810 1.1×	219	7.9k
Vicki Plaks United States	24	3.5k 1.0×	3.3k 1.3×	2.4k 1.3×	257 0.3×	815 1.1×	52	8.1k
Laura E. Benjamin United States	38	6.9k 1.9×	2.6k 1.0×	2.8k 1.5×	487 0.6×	1.2k 1.6×	70	10.8k
Silvana Canevari Italy	49	4.4k 1.2×	3.2k 1.2×	1.4k 0.8×	433 0.5×	601 0.8×	227	8.7k
J Folkman United States	21	6.2k 1.7×	2.6k 1.0×	3.0k 1.6×	451 0.5×	1.2k 1.5×	30	10.3k
Rajmohan Murali United States	51	3.1k 0.9×	4.3k 1.7×	1.6k 0.8×	560 0.7×	2.2k 2.8×	179	8.5k
Alfredo Molinolo United States	60	5.0k 1.4×	3.8k 1.5×	1.7k 0.9×	552 0.7×	1.3k 1.7×	171	10.2k

Countries citing papers authored by David Hardisson

Since Specialization

Citations

This map shows the geographic impact of David Hardisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hardisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hardisson more than expected).

Fields of papers citing papers by David Hardisson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hardisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hardisson. The network helps show where David Hardisson may publish in the future.

Co-authorship network of co-authors of David Hardisson

This figure shows the co-authorship network connecting the top 25 collaborators of David Hardisson. A scholar is included among the top collaborators of David Hardisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hardisson. David Hardisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

López‐Janeiro, Álvaro, Ignacio Ruz‐Caracuel, Carlos E. de Andrea, et al.. (2025). The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas. Cells. 14(21). 1676–1676.

Mendiola, Marta, Victoria Heredia-Soto, Ignacio Ruz‐Caracuel, et al.. (2024). Performance of the Idylla microsatellite instability test in endometrial cancer. Molecular and Cellular Probes. 77. 101976–101976.

Montero‐Calle, Ana, Álvaro López‐Janeiro, Marta Mendes, et al.. (2023). In-depth quantitative proteomics analysis revealed C1GALT1 depletion in ECC-1 cells mimics an aggressive endometrial cancer phenotype observed in cancer patients with low C1GALT1 expression. Cellular Oncology. 46(3). 697–715. 16 indexed citations

Noti, Luca, José A. Galván, Inti Zlobec, et al.. (2023). Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. Frontiers in Medicine. 10. 1110529–1110529.

Gallego, Alejandro, Marta Mendiola, Bárbara Hernando, et al.. (2022). Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer. International Journal of Gynecological Cancer. 32(8). 1009–1016. 10 indexed citations

Ruz‐Caracuel, Ignacio, Victoria Heredia-Soto, Bulat Zagidullin, et al.. (2022). Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. Cancers. 14(4). 912–912. 5 indexed citations

Stolnicu, Simona, María José Brito, Georgia Karpathiou, et al.. (2022). Villoglandular Pattern in HPV-associated Endocervical Adenocarcinoma is Associated With Excellent Prognosis: A Reappraisal of 31 Cases Using IECC and Silva Pattern Classification. International Journal of Gynecological Pathology. 42(3). 270–277. 1 indexed citations

López‐Janeiro, Álvaro, Ignacio Ruz‐Caracuel, Vivian de los Rı́os, et al.. (2021). Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling. Cancers. 13(4). 794–794. 36 indexed citations

Ruz‐Caracuel, Ignacio, Álvaro López‐Janeiro, Victoria Heredia-Soto, et al.. (2021). Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 479(6). 1167–1176. 36 indexed citations

10.

Povedano, Eloy, Víctor Ruiz‐Valdepeñas Montiel, María Gamella, et al.. (2020). Amperometric Bioplatforms To Detect Regional DNA Methylation with Single-Base Sensitivity. Analytical Chemistry. 92(7). 5604–5612. 41 indexed citations

11.

Ruz‐Caracuel, Ignacio, Álvaro López‐Janeiro, Laura Yébenes, et al.. (2019). Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. Cancers. 11(12). 1845–1845. 20 indexed citations

12.

Povedano, Eloy, Eva Vargas, Víctor Ruiz‐Valdepeñas Montiel, et al.. (2018). Electrochemical affinity biosensors for fast detection of gene-specific methylations with no need for bisulfite and amplification treatments. Scientific Reports. 8(1). 6418–6418. 64 indexed citations

13.

Povedano, Eloy, Víctor Ruiz‐Valdepeñas Montiel, Alejandro Valverde, et al.. (2018). Versatile Electroanalytical Bioplatforms for Simultaneous Determination of Cancer-Related DNA 5-Methyl- and 5-Hydroxymethyl-Cytosines at Global and Gene-Specific Levels in Human Serum and Tissues. ACS Sensors. 4(1). 227–234. 65 indexed citations

14.

Povedano, Eloy, Alejandro Valverde, Víctor Ruiz‐Valdepeñas Montiel, et al.. (2018). Rapid Electrochemical Assessment of Tumor Suppressor Gene Methylations in Raw Human Serum and Tumor Cells and Tissues Using Immunomagnetic Beads and Selective DNA Hybridization. Angewandte Chemie. 130(27). 8326–8330. 42 indexed citations

15.

Sarrió, David, Socorro Marıá Rodríguez-Pinilla, David Hardisson, et al.. (2008). Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. Cancer Research. 68(4). 989–997. 842 indexed citations breakdown →

16.

Peinado, Héctor, Gema Moreno‐Bueno, David Hardisson, et al.. (2008). Lysyl Oxidase–Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas. Cancer Research. 68(12). 4541–4550. 167 indexed citations

17.

Moreno‐Bueno, Gema, Pablo J. Fernández-Marcos, Manuel Collado, et al.. (2007). Inactivation of the Candidate Tumor Suppressor Par-4 in Endometrial Cancer. Cancer Research. 67(5). 1927–1934. 72 indexed citations

18.

Reis‐Filho, Jorge S., Peter T. Simpson, Nicholas C. Turner, et al.. (2006). FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas. Clinical Cancer Research. 12(22). 6652–6662. 215 indexed citations

19.

Diego, Juan Ignacio de, et al.. (2002). Encefalocele nasal bilateral sincrónico. Boletín Médico del Hospital Infantil de México. 59(1). 26–30. 1 indexed citations

20.

Nogales, Francisco F., David Hardisson, L Bosincu, et al.. (2002). Adenomatoid Tumors of the Uterus: An Analysis of 60 Cases. International Journal of Gynecological Pathology. 21(1). 34–40. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact